NewAmsterdam Pharma reports Q1 net loss of $48.4M; PREVAIL interim analysis planned for 4Q26

NewAmsterdam Pharma Co N.V.

2026-Q1 EPS reported -$0.40 revenue$3,040,000

Net loss $48.4M for Q1 2026, compared to net loss $39.5M in Q1 2025.
Cash and marketable securities $707.3M at March 31, down from $728.9M at Dec 31, 2025.
Regulatory decisions on obicetrapib from EMA, UK, Switzerland expected in 2H26; potential launches by Menarini in 4Q26 in Germany and UK.
PREVAIL CVOT interim analysis planned for 4Q2026, result expected 1Q2027; trial may stop for efficacy or complete by end of 2027.
Completed enrollment in REMBRANDT Phase 3 (323 patients); RUBENS Phase 3 topline data expected by year-end 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.91

NewAmsterdam Pharma Co N.V. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

NewAmsterdam Pharma Co N.V. filing history →

Source: SEC EDGAR

accession 0001193125-26-210283

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.